Rubicon Completes 85% Acquisition of Arinna Lifesciences

Rubicon Research Limited completed its secondary acquisition of an 85% stake in Arinna Lifesciences Limited on April 30, 2026.
The acquisition, executed per a Share Purchase Agreement, renders Arinna Lifesciences a subsidiary of Rubicon.
This intimation is a regulatory disclosure filed under SEBI Listing Regulations, fulfilling post-transaction compliance.